QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-maintains-market-outperform-on-prelude-therapeutics-lowers-price-target-to-3

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

 prelude-therapeutics-q1-eps-042-beats-047-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 citizens-capital-markets-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

Citizens Capital Markets analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and ma...

 prelude-therapeutics-fy-sales-7000m-beat-2000m-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly sales of $7.000 million which beat the analyst consensus estimate of $2.0...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-lowers-price-target-to-4

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the p...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION